Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer

Frontiers in Medicine

Medicine

Lei Wang¹  Gaoda Ju²  Chonghua Jiang³  Lijuan Zang⁴  Han Diao⁵  Xingzhou Yu⁵  Bing Xue⁵  Rui Zhang⁵  Linlin Zhang⁵  Hua Zhang⁵  Sen Miao⁵  Lihua Zhao⁵  Xiaozao Pan⁵  Tianhao Zhou⁶ 

[1] Department of Breast Surgery, Affiliated Hospital of Jining Medical University, Jining, China;Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China;Department of Neurosurgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China;Department of Pathology Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China;Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China;Department of Breast Surgery, Affiliated Hospital of Jining Medical University, Jining, China;Key Laboratory of Breast Cancer Prevention and Treatment of the Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, China;Department of Medical Oncology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

关键词: DYNLT1;    breast cancer;    biomarker;    prognosis;    immune checkpoint blocking therapy;   

DOI  :  10.3389/fmed.2023.1167676

 received in 2023-02-16, accepted in 2023-03-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundBreast cancer (BC) is the most common malignant disease worldwide. Although the survival rate is improved in recent years, the prognosis is still bleak once recurrence and metastasis occur. It is vital to investigate more efficient biomarkers for predicting the metastasis and relapse of BC. DYNLT1 has been reported that participating in the progression of multiple cancers. However, there is still a lack of study about the correlation between DYNLT1 and BC.MethodsIn this study, we evaluated and validated the expression pattern and prognostic implication of DYNLT1 in BC with multiple public cohorts and BC tumor microarrays (TMAs) of paraffin-embedded tissues collected from the Affiliated Hospital of Jining Medical University. The response biomarkers for immune therapy, such as tumor mutational burden (TMB), between different DYNLT1 expression level BC samples were investigated using data from the TCGA-BRCA cohort utilizing public online tools. In addition, colony formation and transwell assay were conducted to verify the effects of DYNLT1 in BC cell line proliferation and invasion.ResultsThe results demonstrated that DYNLT1 overexpressed in BC and predicted poor relapse-free survival in our own BC TMA cohort. In addition, DYNLT1 induced BC development by promoting MDA-MB-231 cell proliferation migration, and metastasis.ConclusionAltogether, our findings proposed that DYNLT1 could be a diagnostic and prognostic indicator in BC.

【 授权许可】

Unknown   
Copyright © 2023 Miao, Ju, Jiang, Xue, Zhao, Zhang, Diao, Yu, Zhang, Pan, Zhang, Zang, Wang and Zhou.